Stay updated on Pembrolizumab + Palliative Radiotherapy in BC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Palliative Radiotherapy in BC Clinical Trial page.

Latest updates to the Pembrolizumab + Palliative Radiotherapy in BC Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe clinical trial record for pembrolizumab plus palliative radiotherapy in metastatic breast cancer is now displayed instead of an access-denied error. It includes study design, eligibility, outcomes, and the update that the trial terminated at stage 1 for lack of evidence of promise.SummaryDifference51%

- Check14 days agoChange DetectedThe ClinicalTrials.gov site revision shown in the footer changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check21 days agoChange DetectedA site-wide NIH banner announces a terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check28 days agoChange DetectedThe ClinicalTrials.gov page remains a 403 Forbidden error page, with its footer revision label changing from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check35 days agoChange DetectedThe revision identifier in the footer changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check49 days agoChange DetectedA 403 Forbidden error is shown when attempting to access the study record, replacing the usual page content with an access-restricted screen and standard site chrome.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab + Palliative Radiotherapy in BC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Palliative Radiotherapy in BC Clinical Trial page.